KIORA PHARMACEUTICALS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
KIORA PHARMACEUTICALS, INC. (KPRX) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $7.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $2.26M, a 55.11% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $5.41M, a 12.97% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $5.43M, a 6.23% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $5.74M, a 0.14% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $22.41M, a 92.55% increase from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $11.64M.
- KIORA PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $0.00.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $7.66M 10-Q · filed 2026-08-07 | $13.09M derived: sum of 3 quarters · filed 2026-08-07 | $18.83M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $5.41M 10-Q · filed 2026-05-08 | $10.83M derived: sum of 2 quarters · filed 2026-05-08 | $16.57M derived: sum of 3 quarters · filed 2026-05-08 | $21.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $11.17M derived: sum of 2 quarters · filed 2026-03-25 | $16.20M derived: sum of 3 quarters · filed 2026-08-07 | $22.41M 10-K · filed 2026-03-25 |
| 2025-09-30 | $5.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $10.77M derived: sum of 2 quarters · filed 2026-08-07 | $16.98M 10-Q · filed 2025-11-07 | $22.77M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $11.24M 10-Q · filed 2026-08-07 | $17.03M derived: sum of 3 quarters · filed 2026-08-07 | $22.78M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $6.21M 10-Q · filed 2026-05-08 | $12.00M derived: sum of 2 quarters · filed 2026-05-08 | $17.75M derived: sum of 3 quarters · filed 2026-05-08 | $17.85M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $11.54M derived: sum of 2 quarters · filed 2026-03-25 | $11.64M derived: sum of 3 quarters · filed 2026-03-25 | $11.64M 10-K · filed 2026-03-25 |
| 2024-09-30 | $5.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $5.85M derived: sum of 2 quarters · filed 2025-11-07 | $5.85M 10-Q · filed 2025-11-07 | $5.85M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $100.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $100.86K 10-Q · filed 2025-08-08 | $100.86K derived: sum of 3 quarters · filed 2025-08-08 | $100.86K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-05-09 | $0.00 derived: sum of 3 quarters · filed 2025-05-09 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 10-K · filed 2025-03-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |